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doi:10.1016/j.jmii.2011.01.027Background: Hemophagocytic lymphohistiocytosis (HLH) is an uncommon but a potentially life-
threatening condition. Few systematic reviews have been published on the clinical manifesta-
tions, causes, and indicators for prognosis of HLH caused by infections.
Methods: We retrospectively reviewed the medical records of patients diagnosed with HLH
documented by bone marrow study at a teaching hospital between 2000 and 2007. HLH was
defined according to the HLH-2004 diagnostic guidelines, which include fever; splenomegaly;
cytopenia; hypertriglyceridemia; hypofibrinogenemia; and hemophagocytosis evident on path-
ological examination of bone marrow, spleen, or lymph node tissue; low or absent natural
killer cell activity; hyperferritinemia; and high serum levels of soluble CD25. The demographic
characteristics, clinical presentations, laboratory results, and final outcomes were recorded.
The cause of HLH was diagnosed by microbiological, pathological, serological, and molecular
biological methods.
Results: Among the studied patients, 66 had HLH because of noninfectious causes and 30
because of infections. Compared with patients with HLH related to noninfectious causes, those
with HLH related to infections had lower mortality (70% vs. 47%, pZ 0.03). The most common
causative pathogens causing HLH were virus (41%), mycobacteria (23%), bacteria (23%), and
fungi (13%), in that order of frequency. Clinical presentations of HLH were variable and
included fever (90%), tachypnea (83%), tachycardia (80%), hepatosplenomegaly (40%), lymph-
adenopathy (27%), and altered consciousness (23%). Laboratory findings revealed thrombocy-
topenia in 93%, hyperferritinemia in 90%, elevated serum lactate dehydrogenase levels inInfectious Diseases, Department of Internal Medicine, National Taiwan University Hospital, 7
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192 Y.-T. Tseng et al.80%, anemia in 67%, and leukopenia in 60% of the patients. Fourteen patients (47%) died. In
multivariate analysis, age more than 50 years (pZ 0.05; odds ratio [OR], 3.46; 95% confidence
interval [CI], 1.00e15.73), fever not subsiding within 3 days of diagnosing HLH (pZ 0.003; OR,
2.38; 95% CI, 1.21e11.25), and occurrence of disseminated intravascular coagulation as
a complication (pZ 0.009; OR, 3.22; 95% CI, 1.68e10.01) were found to be statistically signif-
icant indicators of mortality in patients with HLH.
Conclusions: The infectious diseases associated with HLH were diverse and resulted in a high
mortality rate. Cases in which the patients were aged more than 50 years, developed DIC, and
had persistent fever even after 3 days of being diagnosed with HLH showed poor prognosis.
Copyright ª 2011, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Hemophagocytic lymphohistiocytosis (HLH) is an important
hematological presentation of various diseases. The inci-
dence of HLH in bone marrow studies of critically ill
patients with cytopenia was 0.8%e4%.1 Hemophagocytosis
can be classified into familial and secondary or acquired
types.2 Familial HLH (FHLH) is associated with a group of
inherited immunodeficiencies, including autosomal reces-
sive inherited Chediak-Higashi syndrome and Griselli
syndrome, as well as the X-linked proliferative syndrome.
Virus infection is usually the most common factor triggering
FHLH. The causes of secondary hemophagocytosis include
malignancies, autoimmune diseases, and infections.2
Sometimes, infection may concurrently be associated with
malignancy in patients presenting with HLH.3
HLH is pathologically characterized by a defect in the
cytotoxicity of natural killer (NK) cells or cytotoxic T cells
and overactivation of macrophages, leading to the engulf-
ment of other blood cells, including erythrocytes, platelets,
leukocytes, and other precursor cells. The pathogenesis of
secondary HLH is not well understood but is believed to
involve dysfunction of NK-T cells and cytolytic T cells and
regulation of macrophages.1,4 This dysfunctional immune
system is activated by various factors, such as malignancies
and infections, which in turn trigger a cytokine storm.
Common pathogens reported to cause HLH include
Epstein-Barr virus (EBV),3,5 cytomegalovirus,6 human immu-
nodeficiency virus (HIV),7,8 hepatitis A virus,9,10 bacteria,11
parasites,12 mycobacterium,13e15 and fungus.16 Further-
more, reports have been published on HLH caused by
malignancy, especially leukemia or lymphoma,6,17,18 and
autoimmune diseases, such as systemic lupus erythematosus
(SLE).
In this study, we aim to investigate the clinical charac-
teristics, treatment, and outcome of patients with HLH




We enrolled adult patients (16 years) who had hemo-
phagocytosis proved by bone marrow biopsy/aspiration at
the National Taiwan University Hospital between January 1,2000 and December 31, 2007 (Fig.). Patients were diag-
nosed with HLH if they satisfied at least five of the following
eight criteria of HLH-2004 diagnostic guidelines19: (1) fever
with temperature 38C; (2) splenomegaly; (3) cytopenia
affecting at least two of three lineages of cells in the
peripheral blood (red blood cells, i.e. hemoglobin level of
<9 mg/dL; platelet count of <100,000/mL; neutrophils of
<1,000/mL); (4) hypertriglyceridemia (fasting serum
triglyceride level of 265 mg/dL) and/or hypofi-
brinogenemia (fibrinogen 1.5 g/L); (5) pathological
evidence in samples of the bone marrow, spleen, or lymph
nodes; (6) low or absent NK-cell activity; (7) hyper-
ferritinemia (ferritin level of 500 mg/L); and (8) high
levels of soluble CD25 (2,400 U/mL).
The clinical data of patients, including age, sex, presence
or absence of underlying systemic illness, dates of hospi-
talization and intensive care unit admission, sites of infec-
tion, diagnosis of causes, invasive procedures, antibiotic
use, physical findings, results of blood biochemical tests, and
duration of hospitalization were recorded from the medical
records by using a standardized data collection format.
For patients with underlying autoimmune diseases, the
symptoms, signs, or laboratory results were recorded to
exclude the possibility of HLH being related to autoimmune
activity. We enrolled only patients who were followed up
regularly and had no symptoms or signs or laboratory tests
indicating flare of autoimmune diseases during hospital
admission. Patients with a history of autoimmune diseases
or active flare-up of autoimmune activity were excluded.
Diagnosis of infectious diseases
The infections were diagnosed on the basis of microbio-
logical, pathological, serological, or molecular biological
methods. HLH because of Mycobacterium tuberculosis
infection was defined by (1) positive results of culture of
sputum, blood, bone marrow, or ascitic fluid or (2) positive
results of the sputum acid-fast stain but negative results of
culture and response to antituberculosis treatment.
Patients with bacterial or fungal infection were defined as
those having clinical symptoms or signs of infections and
who showed bacteria or fungi in clinical specimens
obtained from sterile sites (such as blood, ascitic fluid,
pleural effusion, cerebrospinal fluid, and joint effusion);
pus, tissue, or fluid obtained during surgery or needle
aspiration; or serological tests (cryptococcal antigen). HLH
related to cytomegalovirus or EBV infection were confirmed
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Figure 1. Patient flow chart in this study. aNosocomial infections related to HLH included Burkholderia cepacia (nZ 1) and
Acinetobacter baumannii (nZ 1).
Infection-related hemophagocytic lymphohistiocytosis 193by abnormal measurements of the antibody titer, which
included elevation of serum IgG level to more than 4-fold in
sequential tests, presence of serum IgM, and high titer of
IgG (1:2,560), high titer of serum viral load (104 copies/
mL), or positive results of polymerase chain reaction of
cerebrospinal fluid with encephalitis. Patients with clinical
manifestations suggestive of viral infection and lymph
node/tissue histopathological findings suggestive of viral
infection were defined as having unknown viral infection.
For cases in which more than two pathogens were identified
as causing HLH, the classification of pathogens depended
on the treatment response and the clinical courses.
Mortality was defined as death that occurred within 30
days of diagnosing infection, and death associated with
infection during the same period of hospitalization was
included as a case of mortality.
Statistical analysis
All statistical analyses were performed using the SPSS
software version 16.0 (SPSS Inc., Chicago, IL, USA). Cate-
gorical variables were compared using the c2 or Fisher’s
exact test, whereas noncategorical variables were
compared using Wilcoxon’s rank-sum test. Variables in the
univariate analysis with a p value less than 0.2 were
considered in multivariate analysis by using the multiple
logistic regression method to determine the independent
variables that were associated with mortality. All tests
were two-tailed, and a p value less than 0.05 was consid-
ered significant.Results
In this study, we studied the records of 99 patients diag-
nosed with hemophagocytosis, which was confirmed by
bone marrow aspiration study. A total of 96 patients met
the HLH-2004 diagnostic criteria, including 30 patients with
HLH related to infectious disease and 66 patients with HLH
related to noninfectious diseases (61 with hematologic
malignancies) (Fig. 1). The demographic characteristics of
patients with infection-related HLH are shown in Table 1.
They included 24 males (80%) and 6 females (20%), and 15
of these patients (50%) were aged more than 50 years. The
underlying diseases diagnosed before admission included
cardiovascular disease (eight patients), diabetes mellitus
(six patients), and autoimmune disease (five patients). The
latter included one patient each with adult-onset Still’s
disease, SLE, livedoid vasculitis, Sjogren’s syndrome, and
psoriasis.
The initial presentations and physical findings of the
patients included fever (27, 90%), tachypnea (25, 83%),
tachycardia (24, 80%), altered mental status (7, 23%),
lymphadenopathy (8, 27%), hepatosplenomegaly (12, 40%),
diarrhea (6, 20%), jaundice (6, 20%), and skin rashes (4,
13%). Twelve of the 30 patients (40%) with infection-related
HLH presented with fever of unknown origin. The median
duration from symptom onset to diagnosis of HLH was 34.5
days (range, 13e249 days). The laboratory tests showed
leukopenia in 18 (60%) patients, with 9 of them developing
neutropenia (absolute neutrophil count< 500/mL); anemia
in 20 (67%) patients; thrombocytopenia in 28 (93%)
Table 1 Demographic characteristics, clinical manifestations, laboratory results, and clinical outcomes of 30 patients with
infectious diseases associated with hemophagocystic lymphohistiocytosis
Characteristics Overall (nZ 30) Patients died (nZ 14) Patients survived (nZ 16) p
Age, yr (mean, range) 52.4, 17e86 59.1, 23e86 44.4, 17e80 0.06
Age 50 yr 17 (57) 12 (86) 5 (31) 0.03
Gender, male, n (%) 24 (60) 10 (71) 14 (88) 0.5
Underlying diseases, n (%)
Diabetes mellitus 6 (20) 3 (21) 3 (19) >0.99
Cardiovascular diseases 8 (27) 5 (36) 3 (19) 0.53
Malignancy 2 (7) 2 (14) 0 (0) 0.65
Chronic obstructive pulmonary diseases 1 (3) 1 (7) 0 (0) >0.99
Chronic kidney diseases 2 (7) 2 (14) 0 (0) 0.65
Cirrhosis of liver 2 (7) 1 (7) 1 (6) >0.99
Autoimmune diseases 5 (17) 2 (14) 3 (19) >0.99
HIV infection 2 (7) 0 (0) 2 (13) >0.99
Initial presentations, n (%)
Fever (>38C) 27 (90) 13 (93) 14 (88) >0.99
FUOa 12 (40) 8 (57) 4 (25) 0.07
Tachycardia (>100 beats/min) 24 (80) 12 (86) 12 (75) 0.4
Tachypnea (>20 cycles/min) 25 (83) 14 (100) 11 (69) 0.12
Altered mental status 7 (23) 2 (14) 5 (31) 0.51
Lymphadenopathy 8 (27) 3 (21) 5 (31) 0.85
Hepatosplenomegaly 12 (40) 5 (36) 7 (44) 0.7
Diarrhea 6 (20) 5 (36) 1 (6) 0.06
Skin rashes 4 (13) 1 (7) 3 (19) 0.71
Jaundice 6 (20) 2 (14) 4 (25) 0.79
Laboratory results, n (%)
WBC (<4,000/mL) 18 (60) 7 (50) 11(69) 0.3
Neutropeniab 9 (30) 4 (29) 5 (31) 0.8
Hb (<9 g/dL) 20 (67) 10 (71) 10 (63) 0.9
Platelet count (<100,000/mL) 28 (93) 14 (100) 14 (88) 0.82
Platelet count (<50,000/mL) 23 (77) 13 (93) 10 (63) 0.12
Triglyceride (265 mg/dL) 9 (30) 2 (14) 7 (44) 0.17
LDH (1,000 U/L) 24 (80) 11 (79) 13 (81) >0.99
Ferritin (>500 ng/mL) 27 (90) 13 (93) 14 (88) >0.99
Ferritin (>10,000 ng/mL) 13 (30) 11 (79) 4 (25) 0.52
ALT (80 U/L) 19 (63) 8 (57) 11 (69) 0.51
ALP (400 U/L) 15 (50) 8 (57) 7 (44) 0.46
Infection type, n (%)
Lymphadenitis 3 (10) 2 (14) 1 (6) 0.90
Pneumonia 7 (23) 4 (29) 3 (19) 0.84
Intraabdominal infection 2 (7) 0 (0) 2 (13) 0.95
Urinary tract infection 1 (3) 1 (7) 0 (0) >0.99
Meningitis 1 (3) 1 (7) 0 (0) >0.99
Systemic viral infectionc 5 (17) 1 (7) 4 (25) 0.4
Organism from blood cultures 12 (40) 6 (43) 6 (38) >0.99
Treatment, n (%)
IVIG use 13 (30) 5 (36) 8 (50) 0.43
Immune modulator used 17 (57) 7 (50) 10 (63) 0.5
Clinical course
Became stablee 7 d 9 (30) 1 (7) 8 (50) 0.03
Fever subsided 3 d 11 (37) 2 (14) 9 (56) 0.02
DIC 11 (37) 9 (64) 2 (13) 0.003
a FUO: fever persisting for more than 14 days after visiting twice for medical help.
b Neutropenia, absolute neutrophil count less than 500/mL.
c Systemic viral infections include HIV (nZ 2), Epstein-Barr virus (nZ 1), and cytomegalovirus (nZ 2) infection.
d Immune modulator use includes use of corticosteroid, IVIG, and chemotherapy agents, such as etoposide (VP-16).
e Stable condition was defined as vital signs (body temperature, pulse rate, and respiratory rate) being within the normal range.
ALPZ alkaline phosphatase; ALTZ alanine transaminase; DICZ disseminated intravascular coagulation; FUOZ fever of unknown
origin; HbZ hemoglobin; HIVZ Human immunodeficiency virus infection; IVIGZ intravenous immunoglobulin; LDHZ lactate dehy-
drogenase; WBCZwhite blood cell count.
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more than twice the upper limit of the normal range in 15
(50%) patients; elevation of serum lactate dehydrogenase
level in 24 (80%) patients; hypertriglyceridemia in 9 (30%)
patients; and elevation of serum ferritin level in 10 (33%)
patients (Table 1).
The pathogens associated with HLH are shown in Table
2. The most common causes of HLH were virus infection
(12 patients; 41%), bacterial infections (7 patients; 23%),
M tuberculosis infections (7 patients; 23%), and fungal
infections (4 patients; 13%), in that order of frequency. The
most common identified viral pathogen was EBV (nZ 2). Six
patients had pathological findings and clinical presentation
that was indicative of viral origin. The most common fungal
pathogen causing HLH was Penicillium marneffei (nZ 2).
There were no differences between the different causative
agents of HLH in terms of the presenting symptoms, labo-
ratory findings, and outcomes.
Of the seven patients with M tuberculosis-related HLH,
all were male, with median age of 44 years (range, 17e86
years). M tuberculosis was detected from the sputum
culture by bronchoscopic examination (nZ 2), or blood
(nZ 3), or bone marrow culture (nZ 2). All patients with
M tuberculosis- and fungi-related HLH had chronic systemic
diseases, such as chronic hepatitis B, chronic hepatitis C
(nZ 3), alcoholic liver cirrhosis (nZ 2), diabetes (nZ 2),
HIV infection (nZ 2), SLE (nZ 1), and end-stage renal
disease because of bladder transitional cell carcinoma
(nZ 1). M tuberculosis-related HLH seemed to be associ-
ated with higher mortality rate (71% vs. 39%, pZ 0.14) and
longer duration of symptoms (more than 2 weeks) before
diagnosis (67% vs. 48%, pZ 0.46) than HLH caused by other
infections. However, because the number of cases was
small, the difference was not statistically significant. None
of the seven patients with M tuberculosis-related HLH had
respiratory symptoms or showed pulmonary infiltrations on
chest radiographs. Three of these seven patients wereTable 2 Causative pathogens of hemophagocytic lym-
phohistiocytosis related to infectious disease
Causative pathogen n (%)
Mycobacterium tuberculosis 7 (23)
Bacteria 7 (23)
Staphylococcus aureus 2 (7)
Klebsiella pneumoniae 2 (7)
Nontyphoid Salmonella 1 (3)
Aeromonas hydrophila 1 (3)
Escherichia coli 1 (3)
Fungi 4 (13)
Candida albicans 1 (3)
Penicillium marneffei 2 (7)
Cryptococcus neoformans 1 (3)
Virus 12 (41)
Hepatitis A virus 1 (3)
Human immunodeficiency virusa 2 (7)
Cytomegalovirus 1 (3)
Epstein-Barr virus 2 (7)
Suspect viral origin 6 (21)
a Both patients had primary human immunodeficiency virus
infections.diagnosed with disseminated intravascular coagulation
because of M tuberculosis infection at the initial presen-
tation.20 Five out of the seven patients (71%) with
M tuberculosis-related HLH died. Only three of the five
patients received antituberculosis therapy before their
death.
The overall mortality rate of all-cause HLH was 63% (60
of 96 patients). Compared with patients with HLH because
of noninfectious causes, those with HLH because of infec-
tions had lower mortality (70% vs. 47%, pZ 0.03). The
overall mortality of infection-related HLH was 47% (14
patients). Of the 14 patients who died, 3 received appro-
priate pathogen-specific therapy in the first week. In
multivariate analysis, age more than 50 years [pZ 0.05;
odds ratio (OR), 3.46; 95% confidence interval (CI),
1.00e15.73], fever not subsiding within 3 days of diagnosing
HLH (pZ 0.03; OR, 2.38; 95% CI, 1.21e11.25), and occur-
rence of disseminated intravascular coagulation (DIC) as
a complication (pZ 0.009; OR, 3.22; 95% CI, 1.68e10.01)
were significant factors associated with mortality (Table 3).
Previous reports have described three cases of HLH
because of M tuberculosis infection; two of these were
caused by HIV infection and one was caused by hepatitis A
infection.7,10,20Discussion
In this study, we showed that the infections causing HLH are
diverse and have high mortality in adult Taiwanese
patients. Patients with HLH because of infections had lower
mortality than those who had HLH because of noninfectious
causes (HLH in most such cases was caused by hematologic
malignancies). Thorough investigations, including molec-
ular biological, microbiological, pathological, and serolog-
ical examinations, are recommended for the identification
and early treatment of the cause of HLH. Patients aged
more than 50 years, fever not subsiding within 3 days of
diagnosing HLH, and occurrence of DIC have a high risk for
mortality.
The infection-related HLH mortality rate in this study
was 47%. In previous studies on patients with HLH because
of various causes,11,18e24 the overall mortality rates ranged
between 30% and 80%. The comparison between studies is
difficult because of differences in the study population
(some studies are on children, whereas others are on
adults); underlying diseases with autoimmune conditions,25
malignancy, or lymphoma11,18,24; the diagnostic tools used;
and the possibility of the initial bone marrow study being
negative.2,26 Compatible with other studies,11,18e24 our
results also show a high mortality rate associated with
infection-related HLH.
The causes of infection-related HLH are diverse.18,25
Bacterial, virus, or fungal infection could all be involved
in the pathogenesis of HLH. In this study, M tuberculosis as
well as other pathogens (Staphylococcus aureus, Klebsiella
pneumoniae, Penicillium marneffei, and Candida albi-
cans), were the common causes of infection-related HLH in
adult patients. Although previous studies have reported
that EBV infection is the most common cause of HLH,2,5,19 it
was diagnosed only in a few cases in our study, which may
be attributed to the fact that most patients with EBV
Table 3 Multivariate analysis of factors associated with 30-day mortality in 30 patients with hemophagocytic
lymphohistiocytosis
Factors Patients died (nZ 14) Patients survived (nZ 16) Odds ratio (95% confidence interval) p
Age 50 yr, n (%)
Yes 12 (86) 5 (31) 3.46 (1.00e15.73) 0.05
No 2 (14) 11 (69)
Defervescence 3 d after diagnosis, n (%)
Yes 2 (14) 9 (56) 2.38 (1.21e11.25) 0.03
No 12 (86) 7 (44)
Onset of DIC, n (%)
Yes 9 (64) 2 (13) 3.22 (1.68e10.01) 0.009
No 5 (36) 14 (87)
DICZ disseminated intravascular coagulation.
196 Y.-T. Tseng et al.infection tended to be younger and we excluded this
section of the population in this study. All patients with
M tuberculosis- and fungi-related HLH were immunocom-
promised because of factors, such as diabetes, chronic liver
and renal disease, HIV infection, or immunosuppresion
therapy. In this study, we also noted that patients with
M tuberculosis-related HLH who did not have the typical
symptoms and signs of pulmonary infection were generally
diagnosed late and received late treatment. Detailed
investigations for detection of possible antimicrobial
treatable diseases and administration of appropriate
treatment might improve the prognosis of HLH.
Treatments of HLH include therapy targeted at the
cause of HLH and immune modulators for cytokine storm,
such as intravenous immunoglobulin, etoposide, dexa-
methasone, and cyclosporine A.1,9,19 The HLH-2004 diag-
nostic and therapeutic guidelines suggest treatment of HLH
with a combination of dexamethasone, etoposide, and
cyclosporine A for 8 weeks. However, most evidence-based
treatments for HLH have primarily been proposed for the
treatment of FHLH. In some studies, treatment of the
underlying disease has been suggested as the most efficient
way to treat secondary hemophagocytosis.16,26 There were
no significant differences in the mortality rates between
patients receiving immune modulators and those not
receiving them. However, we examined only a few cases in
this study and the patients usually received immune
modulator treatment at the time of clinical progression of
disease or at a late stage of the disease. It remains to be
determined whether the routine use of immune modulators
or not (cost benefits) or when to use it still remained
debated.
Previous studies have reported the following as factors
associated with mortality because of HLH: underlying
diseases, old age, use of immunosuppressive agents, and
laboratory findings (thrombocytopenia, anemia, DIC, and
high serum ferritin level).18,23e25 In our study, the factors
associated with poor prognosis of infection-related HLH
were age more than 50 years old, development of DIC, and
fever not subsiding even 3 days after HLH was diagnosed.
Patients with these factors should undergo extensive
investigations and should be treated with both antimicro-
bial agents and immune modulators to improve the clinical
outcome.The most important limitations of our study are the
small sample size and the retrospective nature of the study,
which relied on the accurate and complete recording of
many items, such as initial presentation and laboratory
data. Furthermore, the results of the diagnostic tests per-
formed to identify the pathogen may be influenced by the
method used.
In conclusion, infectious diseases associated with HLH
were diverse and resulted in a high mortality rate. Cases in
which patients were elderly, developed DIC, and had
persistent fever should be thoroughly investigated to
identify the cause of HLH; treatment should be aimed at
eliminating the causative agent and provide intensive
supportive measures to improve the outcomes.
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